Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
The evolving role of the optometrist in nonsurgical cataract management
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Dry eye disease insights and new treatments discussed at Optometry’s Meeting 2024
  • Conference Roundup

Dry eye disease insights and new treatments discussed at Optometry’s Meeting 2024

Kelsey Moroz

Dr Sathi Maiti, Periman Eye Institute’s Vice President of Clinical Research, delivered a comprehensive lecture on the latest advancements and ongoing research in the treatment of dry eye disease (DED) at the American Optometric Association’s annual meeting, covering a range of topics from the fundamental understanding of dry eye and meibomian gland dysfunction (MGD) to the most recent innovations in diagnostic tools and treatment options.

According to Dr Maiti, dry eye is a multifactorial disease characterized by a loss of tear film homeostasis, which leads to ocular surface inflammation and neurosensory abnormalities.

A significant portion of the lecture was dedicated to the immunological basis of DED and the “double vicious cycle” of inflammation. Dr Maiti emphasized that inflammation is a key driver of the disease and tackling it early is crucial for effective management. She highlighted various diagnostic tools, from basic methods like slit lamp examination and tear break-up time (TBUT) to advanced techniques such as meibography and tear osmolarity testing.

The burden of DED on patients, doctors, and society was also discussed. Dr Maiti noted that DED imposes an estimated $55.4 billion societal cost in the U.S. alone. In addition, the COVID-19 pandemic has exacerbated DED symptoms due to prolonged mask-wearing, known as Mask Associated Dry Eye (MADE).

In terms of treatment, Dr Maiti reviewed current options and provided practical tips for clinicians, including the importance of thorough patient histories and the use of questionnaires like OSDI and SPEED. She also discussed innovative treatment prospects, including new pharmacological agents and advanced therapeutic approaches such as intense pulsed light therapy.

Special attention was given to under-recognized issues like Demodex infestations and the role of cosmetics in DED. Dr Maiti stressed the importance of addressing Demodex in patients with persistent blepharitis and recommended that clinicians educate their patients on safe cosmetic practices to prevent exacerbation of dry eye symptoms.

Reference
Maiti S. Practical Pearls Plus Prospects in the Pipeline: Dry Eye in 2024. Presented at: Optometry’s Meeting 2024; June 19-22: Nashville.

Share

Related Content

  • Ocular Surface Disease

Childhood-onset allergic eye disease linked to greater ocular morbidity

  • Ocular Surface Disease

Perceived stress may precede worsening dry eye symptoms in young adults

  • Ocular Surface Disease

Post-menopausal women show more severe evaporative dry eye disease

  • Ocular Surface Disease

Dry eye diagnostic practices remain inconsistent worldwide, survey finds

  • Ocular Surface Disease

Spotlight on VEVYE®

  • Ocular Surface Disease

Intervening early in dry eye disease: reducing patient cost and disease burden

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon